Viral safety of plasma‐derived and recombinant products used in the management of haemophilia A and B
- 1 January 1995
- journal article
- Published by Wiley in Haemophilia
- Vol. 1 (S1), 14-20
- https://doi.org/10.1111/j.1365-2516.1995.tb00105.x
Abstract
No abstract availableThis publication has 41 references indexed in Scilit:
- Prospective study of the evaluation of hepatitis C virus infectivity in a high‐purity, solvent/detergent‐treated factor VIII concentrate: parallel evaluation of other markers for lipid‐enveloped and non‐lipid‐ enveloped viruses.Transfusion, 1993
- Low risk of viral infection after administration of vapor-heated factor VIII concentrate. International Investigator GroupTransfusion, 1992
- Transmission of Human Immunodeficiency Virus Type 1 by Dry‐Heated Clotting Factor Concentrates1Vox Sanguinis, 1990
- HIV Seroconversion in Haemophilic Boys Receiving Heat‐Treated Factor VIII ConcentrateVox Sanguinis, 1990
- Absence of Anti-Human Immunodeficiency Virus Types 1 and 2 Seroconversion after the Treatment of Hemophilia A or von Willebrand's Disease with Pasteurized Factor VIII ConcentrateNew England Journal of Medicine, 1989
- A Prospective Study of Human Immunodeficiency Virus Type 1 Infection and the Development of AIDS in Subjects with HemophiliaNew England Journal of Medicine, 1989
- Übertragung von Human-Immunodeficiency-Virus (HIV) durch trocken-hitzebehandelte Faktor- VIII-Gerinnungspräparate?Klinische Padiatrie, 1988
- TRANSMISSION OF HEPATITIS B BY DRY HEAT TREATED FACTOR VIII AND IX CONCENTRATESBritish Journal of Haematology, 1988
- Reduced risk of non‐A, non‐B hepatitis after a first exposure to ‘wet heated’factor VIII concentrateBritish Journal of Haematology, 1987
- Absence of Hepatitis after Treatment with a Pasteurized Factor VIII Concentrate in Patients with Hemophilia and No Previous TransfusionsNew England Journal of Medicine, 1987